ADMA BiologicsADMA -0.54%64 Days Inventory is 579.47 as of Mar. 2026, which is 79% above its 10-year median of 323.69. GuruFocus rates ADMA with a GF Score™ of 64/100 and a GF Value™ of $18.04 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 635 Biotechnology companies, ADMA Biologics ranks worse than 75.28% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). ADMA Biologics's Average Total Inventories for the
three
months ended in Mar. 2026 was $214.3 Mil. ADMA Biologics's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $33.7 Mil.
Hence, ADMA Biologics's Days Inventory for the
three
months ended in Mar. 2026 was 579.47.
The historical rank and industry rank for ADMA Biologics's Days Inventory or its related term are showing as below:
ADMA'
s Days Inventory Range Over the Past 10 Years
Min: 110.43 Med: 323.69 Max: 471.89
Current: 365.61
During the past 13 years, ADMA Biologics's highest Days Inventory was 471.89. The lowest was 110.43. And the median was 323.69.
ADMA's Days Inventory is ranked worse than 75.28% of 635
companies
in the Biotechnology industry
Industry Median: 183.23
vs ADMA: 365.61
ADMA Biologics's Days Inventory
increased
from Mar. 2025 (290.90) to Mar. 2026 (579.47).
It might indicate that ADMA Biologics's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
ADMA Biologics's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.16.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
ADMA Biologics's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 1.87.
ADMA Biologics (NAS:ADMA) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
ADMA Biologics's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
ADMA Biologics's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
ADMA Biologics Days Inventory Related Terms
ADMA Biologics Days Inventory Historical Data
* Premium members only.
The historical data trend for ADMA Biologics's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADMA vs ZLAB, HRMY, STOK: Days Inventory Comparison
For the Biotechnology subindustry, ADMA Biologics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADMA Biologics Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ADMA Biologics's Days Inventory distribution charts can be found below:
* The bar in red indicates where ADMA Biologics's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADMA Biologics (ADMA) has a Days Inventory of 579.47 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on ADMA Biologics and its competitors. This is 79% above median its historical median of 323.69. Over the past decade, ADMA Biologics' Days Inventory has ranged from 110.43 to 471.89. According to the industry distribution chart, ADMA Biologics ranks #478 out of 635 companies in the Biotechnology industry, placing it in the top 75.3%.
Is ADMA Biologics' Days Inventory too high?
ADMA Biologics' current Days Inventory of 579.47 is 79% above median its 10-year median of 323.69. Over the past 10 years, this metric has ranged from a low of 110.43 to a high of 471.89. The Biotechnology industry median Days Inventory is 183.23. ADMA Biologics' value of 579.47 is 216.3% above this industry median. Based on the distribution chart, ADMA Biologics ranks #478 out of 635 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ADMA Biologics has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ADMA Biologics' Days Inventory compare to ZLAB and HRMY?
According to the Biotechnology industry distribution chart, ADMA Biologics ranks #478 out of 635 companies for Days Inventory. This places ADMA Biologics in the lower half of its industry. The industry median Days Inventory is 183.23. ADMA Biologics' value of 579.47 is 216.3% above this benchmark. Historically, ADMA Biologics' own Days Inventory has ranged from 110.43 to 471.89 over the past decade. While the company's 10-year median is 323.69 vs. the industry median of 183.23, ADMA Biologics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.23, based on 635 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ADMA Biologics's current Days Inventory of 579.47 is 216.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on ADMA Biologics and its competitors. For the Biotechnology industry, the median Days Inventory is 183.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ADMA Biologics's current Days Inventory is 579.47, which is 79% above median its own 10-year median of 323.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADMA Biologics stock overvalued right now?
Based on GuruFocus' analysis, ADMA Biologics (ADMA) is currently considered Significantly Undervalued. The stock's GF Value™ is $18.04, compared to a current price of $9.16 — trading 49.2% below its estimated fair value. The current Days Inventory is 579.47, which is 79% above median its 10-year median of 323.69 and 216.3% above the Biotechnology industry median of 183.23. ADMA Biologics' overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For ADMA Biologics (ADMA), the current Days Inventory is 579.47 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADMA Biologics (ADMA) Overvalued in 2026?
Based on GuruFocus' analysis, ADMA Biologics stock appears to be undervalued.
The current stock price of $9.16 is trading 49.2% below its estimated GF Value™ of $18.04.
GuruFocus considers ADMA Biologics to be Significantly Undervalued.
Key valuation signals for ADMA:
Days Inventory: 579.47 (79% above median its 10-year median of 323.69)
GF Value™: $18.04 vs. price of $9.16 (49.2% below fair value)
Industry Position: 216.3% above the Biotechnology median (#478 of 635)
No single metric tells the full story. See the ADMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
64GF Score
Get the complete analysis for ADMA
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADMA has been successfully added to your 
